$1.65+0.03 (+1.85%)
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
Neumora Therapeutics, Inc. in the Healthcare sector is trading at $1.65 with a market capitalization of $322M. Wall Street consensus targets $8.91 (8 analysts), implying a +439.8% move over the next 12 months. The stock is currently 55% below its 52-week high of $3.65, remaining 25.0% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant...
SoftBank fully exited Circle Internet Group in Q1 2026. Here is what investors need to know about the stablecoin giant's fundamentals.
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is featured in our list of the best penny stocks set to explode. As of April 8, 2026, analyst sentiment toward Neumora Therapeutics, Inc. (NASDAQ:NMRA) remains bullish, with 78% of analysts assigning a “Buy” rating to the stock. The consensus price target of $8 implies a potential upside of 275.59%. Reinforcing […]
Moby summary of Neumora Therapeutics, Inc. Common Stock's Q4 2025 earnings call
Neumora Therapeutics Inc (NMRA) showcases promising clinical developments and a robust cash runway, despite facing setbacks in toxicology studies.
Neumora Therapeutics (NASDAQ:NMRA) outlined clinical and pipeline updates alongside its fourth-quarter and full-year 2025 financial results, highlighting multiple anticipated data catalysts in 2026 and providing additional detail on several preclinical and clinical programs. Management highlights “